Effects of metformin on inappropriate LH release in women with polycystic ovarian syndrome and insulin resistance (Q42497236)

1 November 2017

Effects of metformin on inappropriate LH release in women with polycystic ovarian syndrome and insulin resistance (English)

1 reference

1 November 2017

1 reference

4

1 reference

1 November 2017

6

1 reference

1 November 2017

Alfredo Ulloa-Aguirre

1

1 reference

1 November 2017

Lesly Portocarrero

2

1 reference

1 November 2017

Teresa Zariñán

3

1 reference

1 November 2017

Sebastián Carranza-Lira

5

1 reference

1 November 2017

Juan C López-Alvarenga

7

1 reference

1 November 2017

1 June 2006

1 reference

Reproductive BioMedicine Online

1 November 2017

1 reference

1 November 2017

12

1 reference

1 November 2017

6

1 reference

1 November 2017

669-683

1 reference

Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells

1 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Prevalence and characteristics of early-onset type 2 diabetes in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Metformin directly inhibits androgen production in human thecal cells

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

The prevalence and features of the polycystic ovary syndrome in an unselected population

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Is there a physiological role for gonadotrophin oligosaccharide heterogeneity in humans? III. Luteinizing hormone heterogeneity: a medical physiologist's perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Vaginal progesterone administration before ovulation induction with exogenous gonadotropins in polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease (PCOD) and non-PCOD secondary amenorrhea

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

A preponderance of circulating basic isoforms is associated with decreased plasma half-life and biological to immunological ratio of gonadotropin-releasing hormone-releasable luteinizing hormone in obese men.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Pituitary responsiveness to gonadotrophin-releasing hormone agonist stimulation: a dose-response comparison of luteinizing hormone/follicle-stimulating hormone secretion in women with polycystic ovary syndrome and normal women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

The molecular characteristics of polycystic ovary syndrome (PCOS) ovary defined by human ovary cDNA microarray

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Preponderance of basic isoforms of serum luteinizing hormone (LH) is associated with the high bio/immune ratio of LH in healthy women and in women with polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Obese Patients with Polycystic Ovary Syndrome: Evidence that Metformin Does Not Restore Sensitivity of the Gonadotropin-Releasing Hormone Pulse Generator to Inhibition by Ovarian Steroids

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Polycystic Ovary Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Role of progesterone deficiency in the development of luteinizing hormone and androgen abnormalities in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Recruitment prior to ovarian stimulation: ways of improving follicular recruitment

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Augmented frequency and mass of LH discharged per burst are accompanied by marked disorderliness of LH secretion in adolescents with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Reconstruction of in vivo time-evolving neuroendocrine dose-response properties unveils admixed deterministic and stochastic elements

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Poorly controlled type I diabetes mellitus in young men selectively suppresses luteinizing hormone secretory burst mass

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovary syndrome despite improved insulin sensitivity during pioglitazone treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Polycystic ovary syndrome is associated with endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Increased Luteinizing Hormone Secretion in Women with Polycystic Ovary Syndrome Is Unaltered by Prolonged Insulin Infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Approximate entropy as a measure of system complexity

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Leptin concentrations in hirsute women with polycystic ovary syndrome or idiopathic hirsutism: influence on LH and relationship with hormonal, metabolic, and anthropometric measurements.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Deconvolution analysis of hormone data

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Disruption of the joint synchrony of luteinizing hormone, testosterone, and androstenedione secretion in adolescents with polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Thyrotropin Suppression by Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Inappropriate Secretion of Follicle-Stimulating Hormone and Luteinizing Hormone in Polycystic Ovarian Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Receptor binding activity and in vitro biological activity of the human FSH charge isoforms as disclosed by heterologous and homologous assay systems: implications for the structure-function relationship of the FSH variants

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

Changes in the biological:immunological ratio of basal and GnRH-releasable FSH during the follicular, pre-ovulatory and luteal phases of the human menstrual cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961079-6

7 January 2021

10.1016/S1472-6483(10)61079-6

Identifiers

DOI

1 reference

1 November 2017

1 reference